Thor Medical   Report issue

For profit Phase 1 Phase 2
Founded: Oslo Norway (2009)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2012
NCT01796171
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Nordic Nanovector